Pain Pump Plaintiff’s Promotion-Based Punitives Precluded

by Dechert LLP
Contact

It’s déjà vu all over again.  Taking a rather tattered page from the Bone Screw plaintiffs’ spectacularly unsuccessful playbook of a decade ago, at least some plaintiffs in the every-man-for-himself Pain Pump litigation are trying to turn truthful promotion of off-label use (which the FDA – running roughshod over the First Amendment – regards as illegal) into a tort.

It’s not, and while off-label promotion may be illegal, “[t]he FDCA leaves no doubt that it is the Federal Government rather than private litigants who are authorized to file suit for noncompliance with the medical device provisions.”  Buckman Co. v. Plaintiff’s Legal Committee, 531 U.S. 341, 349 n.4 (2001).  This statute (21 U.S.C. §337(a)) is “clear evidence that Congress intended that the MDA be enforced exclusively by the Federal Government.”  Id. at 352.

We’re pleased to report that, in Healey v. I-Flow, LLC, ___ F. Supp.2d ___, 2012 WL 1185680 (D. Minn. April 10, 2012), the court squashed an FDCA-based illegal promotion claim when masquerading as a claim for punitive damages.  Basically, plaintiff argued that, because the defendants allegedly promoted an “inadequately tested” off-label use, they should be liable for punitive damages.  Id. at *2.  The inadequate testing claim was basically tautological – grounded in the FDA’s refusal to clear the device for the use in question – which is what made it an off-label use in the first place:

"Plaintiff . . . seek[s] punitive damages because Defendants . . . market[ed] and promot[ed] the pain pump without researching or testing the safety of its use in intra-articular sites, by disregarding the FDA’s denial of clearance, and by failing to inform doctors and patients of the FDA’s denial."

Id.

So the alleged duties in Healey appear to be:  (1) not researching uses that aren’t cleared by the FDA and thus can’t appear on the label anyway, (2) off-label promotion of a use the FDA declined to clear, and (3) not telling everybody that the FDA declined to clear that use.

Such claims suffer from a couple of existential problems.  First of all, FDA non-clearance doesn’t relate to safety.  The Supreme Court emphatically held in Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996), that the “substantial equivalence” standard for FDA device clearance isn’t safety-related – if it had been, the state-law claim would have been preempted:

"The [defendant] exaggerates the importance of the § 510(k) process. . . . [T]he 510(k) process is focused on equivalence, not safety.  As a result, “substantial equivalence determinations provide little protection to the public.  These determinations simply compare [devices] to ascertain whether the later device is no more dangerous and no less effective than the earlier device.  If the earlier device poses a severe risk or is ineffective, then the later device may also be risky or ineffective." 

518 U.S. at 493 (emphasis partially original).  Thus, substantially equivalent devices – like the pain pump in Healey – have “never been formally reviewed under the MDA for safety or efficacy.”  Id.

So FDA clearance, yes or no, isn't a reflection on the device's safety.

Secondly, these aren’t tort allegations – they’re regulatory.  If there wasn’t an FDA, the concept of off-label promotion (truthful or otherwise) wouldn’t exist.  Ditto for claims based on the FDA declining to clear the device.  These are the sorts of “solely” regulatory claims that Buckman holds do not exist by virtue of exclusive federal FDCA enforcement: 

"We must also reject [plaintiff’s] attempt to characterize both the claims at issue . . . as “claims arising from violations of FDCA requirements”. . . .  [T]he [Lohr] claims arose from the manufacturer’s alleged failure to use reasonable care in the production of the product, not solely from the violation of FDCA requirements.  In the present case, however, the . . . claims exist solely by virtue of the FDCA disclosure requirements.  Thus, [Lohr] does not and cannot stand for the proposition that any violation of the FDCA will support a state-law claim."

531 U.S. at 352-53 (emphasis added))

Thus, under Lohr claims grounded in whether the FDA cleared or did not clear a particular use of a particular device are simply beside the point in a product liability suit, since that clearance doesn’t even involve safety.  And under Buckman, a private plaintiff has no standing to bring off-label promotion claims in the first place, since such claims have nothing to do with traditional torts and everything to do with alleged FDCA violations.

Thus, in the tort context, while a manufacturer’s promotion of off-label use can violate the FDCA, “off-label marketing of an approved drug is itself not inherently fraudulent.”  In re Actimmune Marketing Litigation, 614 F.Supp.2d 1037, 1051 n.6 (N.D. Cal. 2009), aff’d, ___ Fed. Appx. ___, 2011 WL 6887072 (9th Cir. Dec. 30, 2012) (affirmed “for the reasons set forth in the district court's orders”).  Thus, off label promotion, without more, is not tortious.
 

"[P]romotion of the off-label uses of a FDA-approved drug concerns lawful activity and is not inherently misleading. . . . Promotion of off-label uses is not inherently misleading simply because the use is off-label. . . . [The defendant’s promotion] was directed at physicians who are familiar with the FDA-approval process and able to independently evaluate the validity of their claims. Given the sophistication of the audience to whom the off-label uses were promoted, this Court cannot conclude, at this stage of the proceedings, that [defendant's] speech was inherently misleading."
 

United States v. Caronia, 576 F. Supp.2d 385, 397 (E.D.N.Y. 2008).  Accord Central Regional Employees Benefit Fund v. Cephalon, 2009 WL 3245485, at *4 (D.N.J. Oct. 7, 2009) (“[m]erely alleging that [defendant] marketed the drugs at issue for off-label purposes does not state a claim for fraud”); In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, 2009 WL 2043604, at *10 (D.N.J. July 10, 2009) (plaintiff’s “theory of injury requires the Court to assume that off-label promotion is, by its very nature, fraudulent conduct.  This is not reality”; theory“is plainly an impermissible attempt by Plaintiffs to turn violations of the FDCA for off-label promotion into a private right of action”).

As the principles of Lohr and Buckman make clear, more than off-label promotion is needed to state a claim under state tort law.  Both falsity and causation are necessary:

"[I]nsofar as Plaintiffs' claims are based solely on allegations that Defendants promoted [the drug] for off-label purposes, they constitute an impermissible attempt to bring a private suit for violations of the FDCA . . . .  The Court grants Plaintiffs leave to amend their complaint to allege . . . that Defendants . . . engag[ed] in deceptive advertising that fraudulently misrepresented the safety of off-label uses of [the drug].  To be clear, the Court emphasizes that Plaintiffs may not rely on allegations that Defendants engaged in off-label promotion of [the drug]; instead, Plaintiffs must point to specific misrepresentations."
 

In re Epogen & Aranesp Off-Label Marketing & Sales Practices Litigation, 590 F.Supp.2d 1282, 1292 (C.D. Cal. 2008), accord In re Epogen & Aranesp Off-Label Marketing & Sales Practices Litigation, 2009 WL 1703285, at *4 (C.D. Cal. June 17, 2009) (dismissing amended complaint for similar reasons)

Which leads us back to Healey.  Forgetting about off-label promotion for a moment, it is of course possible for a plaintiff to base a claim upon a manufacturer’s false statements about its product.  Off-label use is neither here nor there – a misrepresentation might, or might not, relate to that particular aspect of the product.

But there has to be a false statement of some sort.

And when punitive damages are involved, as in Healey, there has to be scienter, that is the defendant has to know whatever it said was false.  “[P]unitive damage laws . . . punish the same type of conduct – conduct that amounts to a deliberate act with knowledge of facts that make harm very likely.”  2012 WL 1185680, at *5.

Healey then examined the regulatory history – §510k clearance, or else the suit would have been preempted under Riegel v. Medtronic, Inc., 552 U.S. 312 (2008) – and concluded, as Lohr makes clear, that the FDA’s refusal to clear pain pumps specifically for “intra-articular” (a fancy word for between the bones of a joint) use, wasn’t any determination that this use was unsafe:

"There is nothing . . . to show that the FDA ever concluded that use of the [device] in the intra-articular joint space after orthopedic surgery was not safe and effective.  At most, the FDA was simply saying that . . . it would require additional information to determine the safety and effectiveness of the device [and defendant] had not submitted such information.  Significantly, the FDA did not require any contraindication labeling to warn surgeons about using the pain pump in the intra-articular space."

2012 WL 1185680, at *8.  Thus, the FDA’s not clearing the device did not establish any risk of harm, let alone a “very likely” risk.

Nor, at the time of the defendant’s dealings with the FDA, was there any evidence that the defendant “knew that there was any risk that use of the [device] in the intra-articular space would cause” the harm that the plaintiff alleged.  Id.  The lack of clearance itself wasn’t a safety determination, and the record showed that actual knowledge of this particular risk of harm lay far in the future.  Absence of scienter was to be expected from the FDA’s refusal of “substantial equivalence” clearance:
 

"[N]o infusion pumps of any manufacturer had been cleared with orthopedic indications and . . . a company would be most likely required to submit clinical data [to market for that use]."
 

Healey, 2012 WL 1185680, at *8.  Well, duh.  For “equivalence” to exist, there has to be something for a device to be equivalent to.  No predicate use existed, so the device couldn’t be cleared.  But the same lack of predicate use necessarily defeated guilty knowledge, since without any use, no adverse events would have occurred either.  Non-clearance “does not constitute prima facie evidence that [defendant] had any information from testing or otherwise that [the use] was not safe.  Id. at *9 (emphasis added).

If Carl Sagan had been a judge (and were still alive), he would have added that, “absence of evidence [of safety] is not evidence of absence [of safety].”
So all that’s left in Healey was off-label marketing.  But off-label use itself is 100% legal, 2012 WL 1185680, at *9 (quoting Buckman), and illegal promotion, without more, is not tortious.  To make a tort, the off-label promotion must also be false.  And that’s precisely where the plaintiff’s claim foundered in Healey:

"Plaintiff provides no authority for the proposition that it was inappropriate for an . . . sales representative to educate an orthopedic surgeon who chose to use the pain pump in this off-label manner . . . .  But again, Plaintiff provides no evidence that [defendants] withheld [any] information because they knew, or had any reason to know, that . . . use of the [the device] for post-operative pain management after orthopedic surgery would cause [the alleged harm]."

2012 WL 1185680, at *10.  The plaintiff simply failed to prove any false statement knowingly made – or indeed any false statement at all.  Off-label promotion is illegal (putting the First Amendment aside), but by itself it sure ain’t a tort.  Accord Prohaska v. Sofamor, S.N.C., 138 F. Supp.2d 422, 446 (W.D.N.Y. 2001) (off-label promotion claim dismissed; “no proof of a specific false statement made by defendants upon which [the prescriber] relied”); Samarah v. Danek Medical, Inc., 70 F. Supp.2d 1196, 1208 (D. Kan. 1999) (same; “even if it were the case that defendants' conduct constitutes a violation of the MDA, that fact, standing alone, would be insufficient to establish plaintiff's entitlement to recovery”); Sita v. Danek Medical, Inc., 43 F. Supp.2d 245, 263-64 (E.D.N.Y. 1999) (same; “no reasonable juror would find that [the prescriber’s] decision . . . was the result of [defendant’s] alleged illegal marketing scheme”); Parks v. Danek Medical, Inc., 1999 WL 1129706, at *8 n.17 (N.D. Ind. June 17, 1999) (same; “there is no legal duty, enforceable in tort, requiring [defendant] to refrain from [acts constituting off-label promotion]); Bradley v. Danek Medical, Inc., 1999 WL 1866401, at *5-6 (W.D. Tenn. March 26, 1999) (same; prescriber “never decided to utilize [the] devices based on FDA approval status”) (sixteen similar decisions authored by same judge); Leigh v. Danek Medical, Inc., 28 F. Supp.2d 401, 406 (N.D. Tex. 1998) (same; “there is no evidence that plaintiff's surgeon . . . was in any way defrauded”); Moses v. Danek Medical, Inc., 1998 WL 1041279, at *6 (D. Nev. Dec. 11, 1998) (same; “[a]ssuming arguendo that Defendants promotion . . . was illegal, there is no indication that Defendants’ actions were the proximate cause”).

Thus the plaintiff’s illegal-promotion-based punitive damages claim crashed and burned in Healey. We’re not surprised in the least.  Pain Pump plaintiffs are making the same shopworn arguments about “illegal” off-label use in the context of §510k-cleared medical devices that were tried and found wanting over a decade ago in Bone Screw litigation.

There’s no reason to linger any longer at the accident scene. Move along, nothing to see here.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP
Contact
more
less

Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.